Business
Greenwich LifeSciences Provides Update on Corporate Events
STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company
About this update from Greenwich Lifesciences, Inc.
[{"type":"text","content":"STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the \"Company\"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on corporate events. The Company's 2024 events to date are listed below: Feb 29 - Mar 1, 2024 – GBG Annual Scientific Meeting (German clinical network conference)Jun 1 - 4, 2024 – American Society of Clinical Oncology (ASCO) Annual MeetingJun 3 - 6, 2024 – BIO International Convention (partnering conference)Jun 4 - 6, 2024 – Jefferies Global Healthcare ConferenceSep 9 - 10, 2024 – H.C. Wainwright 26th Annual Global Investment ConferenceOct 5, 2024 – Komen Houston Race for the Cure (sponsor)Nov 4 - 6, 2024 – 30th Annual BIO-Europe Fall 2024 (partnering conference)Nov 7, 2024 – 13th Annual Texas Life Science Forum (guest speaker) The Company's planned upcoming events are listed below: Nov 19 - 21, 2024 – Jefferies London Healthcare ConferenceDec 10 - 13, 2024 – San Antonio Breast Cancer Symposium (SABCS)Dec 19, 2024 – Annual Meeting of StockholdersFeb 10 - 11, 2025 – BIO CEO & Investor ConferenceMar 6 - 7, 2025 – GBG Annual Scientific Meeting About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US clinical sites from university-based hospitals and cooperative networks with plans to expand into Europe and to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample s...